Introduction
Each year, approximately 70 000 people are diagnosed with B-cell lymphomas in the United States alone. 1 Although therapy with the anti-CD20 antibody rituximab is highly effective, it is not a cure, especially for the indolent lymphoid malignancies, and 22 000 patients die annually. [2] [3] [4] [5] Thus, novel therapeutics with alternative mechanisms of B-cell killing are needed. 2, 3 Numerous antibodies for B-cell depletion therapy are in clinical development, 3, [6] [7] [8] and 2 immunotoxins (BL22 and CMC-544) target CD22, a B-lymphocyte-specific receptor. In contrast to CD20, CD22 undergoes constitutive endocytosis and is well suited for efficient delivery of the toxin into the cell. 6, [8] [9] [10] [11] CD22 is also a member of the sialic acid binding Ig-like lectin (siglec) family that recognizes glycan ligands found on glycoproteins and glycolipids, and shows a marked preference for ␣2-6-linked sialic acid ligands, which interact with the binding site on the extracellular domain of CD22. 12, 13 As an alternative to antibodies, nanoparticles that are targeted to single cell types have gained attention for their potential to provide selective delivery of therapeutic agents with reduced side effects. 14 Liposomal nanoparticles are pharmaceutically proven delivery vehicles that can encapsulate a therapeutic agent and also display ligands that target cell-surface receptors. 15 The challenge has been to identify a ligand that provides sufficient selectivity for the targeted cell. Certain high-affinity small-molecule ligands (eg, folate) are efficient at targeting cognate receptors expressed at higher levels on the target cell, but lower expression levels on other cell types reduce selectivity. 16, 17 Immunoliposomes use antibodies as targeting agents, but have not to date provided a therapeutic index commensurate with their promise. 18, 19 Several reports have documented the potential of glycan ligands for targeting glycan-binding proteins that exhibit restricted expression on immune cell subsets or inflamed endothelial cells. [20] [21] [22] [23] [24] Based on our previous finding that multivalent synthetic highaffinity glycan ligands of CD22 are efficiently bound and internalized by B cells in vitro, 25, 26 we developed CD22 ligand-decorated liposomal nanoparticles for in vivo targeting B lymphoma cells. In contrast to the approved liposomal doxorubicin (Doxil; Centocor Ortho Biotech Products), which passively delivers doxorubicin (dox) to solid tumors via leaky blood vessels, 27, 28 dox-loaded liposomes bearing ligands of CD22 are actively targeted to and endocytosed by B cells, and significantly extend life in a murine model of human B-cell lymphoma. Moreover, as described here, the ligand-decorated liposomes recognize and kill malignant B cells in peripheral blood samples from patients with lymphoma in proportion to the amount of CD22 expressed, allowing identification of patient populations that would likely benefit from this targeted chemotherapeutic approach.
Methods

Preparation of liposomes
Distearoyl phosphatidylcholine (DSPC), cholesterol (chol), nitrobenzoxadiazol-phosphoethanolamine (NBD-PE), and polyethyleneglycol-distearoyl phosphoethanolamine (PEG-DSPE) were purchased from Avanti Polar Lipids and NOF Corporation. BPC NeuAc-PEG-DSPE was prepared by coupling 9-N-biphenylcarboxyl-NeuAc␣2-6Gal␤1-4GlcNAc ( BPC NeuAc) sialosides 25 with an ethylamine linker to N-hydroxysuccinimide (NHS)-activated pegylated lipids (NOF Corporation; see supplemental Methods, available on the Blood Web site; see the Supplemental Materials link at the top of the online article). Nontargeted naked liposomes were composed of DSPC:Chol:PEG-DSPE in a 60:35:5 molar ratio. CD22-targeted BPC NeuAc liposomes substituted BPC NeuAc-PEG-DSPE for PEG-DSPE on a molfor-mol basis. For preparation of liposomes, lipids dissolved in chloroform and dimethyl sulfoxide were mixed and lyophilized for 16 hours. The lipid flakes were hydrated in the cell culture-grade water to achieve a final liposome concentration of 10mM (total phospholipids) before extrusion through polycarbonate membrane filters (Millipore) with controlled pore sizes of 0.4, 0.2, and 0.1 m. To prepare fluorescently labeled liposomes, 1 mol % of NBD-PE was added into the lipid mixture. Remote loading of dox (Sigma) was obtained using gradients of ammonium sulfate. 29 Liposomes were hydrated in 250mM ammonium sulfate followed by extrusion and dialysis against 290mM glucose at 4°C for at least 4 changes of buffer. Dox was added to the liposome suspension in a ratio of dox/phospholipids equaling 1:7.5 (mass/mass) and incubated at 65°C for 40 minutes. The unbound drug was separated from liposomes by passing the suspensions through a Sepharose CL-4B (GE Healthcare) column equilibrated in 5% glucose (approximately 20-mL column for 2-mL sample). Concentration of encapsulated dox was determined using a fluorescence plate reader at excitation (Ex) of 485 nm and emission (Em) of 590 nm after complete lysis of liposomes by 0.5% Triton X-100. The loading efficiency of doxorubicin was greater than 90%. Liposomes prepared using this method had a mean particle size of 100 nm plus or minus 10 nm in diameter and were confirmed by a Malvern instrument.
Cell lines and binding assay
Daudi Burkitt lymphoma cells were maintained in RPMI-1640 (Invitrogen) containing 10% fetal bovine serum (FBS). Wild-type Chinese hamster ovary (CHO) cells or CHO cells expressing human CD22 were cultured in Dulbecco modified Eagle medium (DMEM)/F12 supplemented with 10% FBS and 100 g/mL phleomycin (Invitrogen) or 500 g/mL Hygromycin-B (Roche), respectively. CHO cell lines expressing Siglec-F and Siglec-E were prepared essentially as described earlier. 30 CHO lines expressing other human or murine siglecs were generously provided by P.R.C. (University of Dundee, Scotland) and Dr Yasuhiro Hashimoto (Riken, Japan). CHO siglec lines were maintained in F10 medium (Invitrogen) supplemented with 10% FBS. TSn cells 31 that overexpress human sialoadhesin (Sn) was a gift from Dr Hans Rempel and Dr Lynn Pulliam (University of California, San Francisco). TSn was cultured in RPMI-1640 containing 10% FBS and 1 g/mL gentamicin (Invitrogen). A20, a murine B-cell line, was maintained in RPMI-1640 with 10% FBS. Unless otherwise stated, the liposomebinding assay was conducted by incubating cells in the mouse or human serum (MP Biomedicals) at 10 6 cells/100 L with the presence of fluorescently labeled liposomes at 200M (total phospholipids). After incubation at 37°C for 1.5 hours, cells were washed followed by fluorescence-activated cell sorter (FACS) analysis.
Fluorescence microscopy
CHO cells expressing CD22 were plated to a coverslip to achieve a 90% confluence followed by incubating with fluorescent liposomes at 37°C for 1 hour. Cells were fixed with 4% paraformaldehyde and stained with PE.Cy5-conjugated anti-human CD22 (BD Pharmingen). For detecting endosomes, fixed cells were permeabilized with 0.05% saponin and stained with anti-EEA1 (BD Pharmingen) followed by AlexaFluor 555-conjugated anti-mouse IgG (Invitrogen). Finally, the specimens were mounted on a slide using mounting solution (Invitrogen) containing DAPI that stains nuclei. Images were taken and processed using a Zeiss fluorescence microscope with a 40ϫ/0.6 oil objective lens (numeric aperature: 0.35; WD: 70 mm), an Axiocam MRm camera (Carl Zeiss), and Axiovision 4 acquisition software.
In vitro cytotoxicity assay
Daudi B lymphoma cells were incubated with dox in free form or entrapped in the naked or BPC NeuAc liposomes at 37°C for 1 hour. Dox concentrations ranging from 1nM to 1mM were examined. Cells were washed and seeded on a 96-well plate at 10 5 cells/100 L growth media, which allowed for an additional 48 hours of incubation followed by determining cell viability using CellTiter 96 (Promega) to measure the activity of enzymes that reduce a tetrazole (MTT) to formazan. The maximum cell viability was defined as medium-treated (untreated) cells. The complete killing was determined as Triton X-100 (0.5%) lysed cells. Data were analyzed using Prism nonlinear regression software (GraphPad Software) for the curve-fitting and determination of IC 50 values. In the case of the clinical samples, we followed the method described by Kreitman et al 8 with modifications. In brief, peripheral blood monocytes were purified using FicollPaque (GE Healthcare) and subjected to liposomal doxorubicin at 10 or 40M or medium-treated for 1 hour at 37°C. Cells were thoroughly washed and seeded on a 96-well plate at 10 6 cells/100 L in RPMI-1640 supplemented with 10% FBS and 2-mercaptoethanol. Cell viability was determined as described on day 5 of incubation.
Mice and pharmacokinetics studies
The Institutional Animal Care and Use Committee of The Scripps Research Institute (TSRI) approved all experimental procedures involving mice. Nonobese diabetic-severe combined immunodeficiency (NOD-SCID) mice were produced by the TSRI breeding colony. Sialoadhesin (Sn) knockout mice were provided by P.R.C. Naive or Daudi tumor-bearing mice (3 mice per group) were intravenously injected with liposomal dox (3 mg/kg). At 0.5, 2, and 25 hours after liposome injection, a sample of blood (100 L) was drawn from mice by making a tail nick and collected in a tube containing 10 L of EDTA to prevent plasma from clogging. Plasma (50 L) was separated from the blood cells by centrifugation and was mixed with 200 L of 5% Triton X-100, 250 L of distilled water, and 1500 L of acidified isopropanol containing 0.75N HCl. Samples were stored at Ϫ20°C overnight for protein precipitation. After removal of the precipitated protein, an aliquot (100 L) of the solution containing plasma samples or dox standards were subjected to the analysis for the concentration of the extracted doxorubicin using a fluorescence plate reader at Ex of 485 nm and Em of 590 nm. The data were analyzed using the Prism software. For macrophage depletion, the SCID mice received 200 L of liposomal clodronate intravenously 32 at 2 days before the injection of the liposomal formulations of dox.
In vivo efficacy studies
Female NOD-SCID mice (6 to 8 weeks old) were injected with 5 ϫ 10 6 Daudi cells at the lateral tail vein intravenously on day 0 (8-10 per group). At days 1 and 3 after tumor injection, animals received intravenous treatments of PBS or 3 mg/kg dox encapsulated in the naked or BPC NeuAc liposomes (in 150 L of 5% glucose). Animals were monitored every other day until the end of the study at day 100 and were killed at the onset of hind-leg paralysis. Survival rate was analyzed using a Kaplan-Meier plot. For detecting residual Daudi tumor cells in the bone marrow, paralyzed or long-term survivor animals were killed, followed by the harvest of bone marrow cells from both femurs. Washed cells were stained with anti-human CD19 or isotype antibodies to identify Daudi tumor cells before FACS analysis.
Clinical subjects
The procedures involving human subjects were reviewed and approved by TSRI Institutional Review Board. We obtained normal blood from TSRI's Normal Blood Donor Service and peripheral blood samples from patients seen by physicians of the Scripps Clinic Medical Group. Eligible patients with untreated or progressive lymphomas and leukemias gave informed consent before participation in this study. Whole blood was freshly collected into EDTA-coated tubes and was analyzed within 24 hours. Fluorescent liposomes were directly added into an aliquot of 100 L of whole blood and incubated at 37°C for 1.5 hours, followed by the lysis of red blood cells. Cells were resuspended in 100 L of Hanks buffered salt solution (HBSS) buffer containing 5% bovine serum albumin (BSA) and incubated with antibodies for detecting surface markers at room temperature for an additional 30 minutes. The following anti-human antibodies purchased from BD Pharmingen were used in the study: anti-CD5 (L17-F12), anti-CD19 (HIB19), anti-CD20 (L27), anti-CD22 (HIB22), anti-CD103 (Ber-ACT8), and anti-(TB28-2) and anti-light chains (1-155-2). Cells were washed twice before FACS analysis. Data were analyzed using FlowJo software (TreeStar).
Statistical analysis
We performed analysis of variance (ANOVA) and 2-sample t test for statistical analysis. We determined significant difference in survival studies using Kaplan-Meier plots and the Mantel-Cox rank test.
Results
CD22-targeted liposomes are bound to and internalized by CD22-expressing cells
To prepare CD22-targeted liposomes, we coupled a high-affinity glycan ligand of CD22, BPC NeuAc, 25 to a commercially available NHS-activated pegylated lipid, and the corresponding BPC NeuAcpegylated lipid was then incorporated into a liposomal doxorubicin formulation ( Figure 1A-B) analogous to that in current clinical use. Fluorescently labeled BPC NeuAc liposomes bound robustly to CD22-expressing but not wild-type CHO cells, whereas the nontargeted "naked" liposomes exhibited no binding to either (Figure 2A ). Fluorescence microscopy shows staining of CD22-expressing cells only by BPC NeuAc liposomes ( Figure 2B) , with diffuse staining of the cell surface, and punctate staining consistent with internalization by endocytosis, as evidenced by costaining with markers of early endosomes (anti-EEA1; Figure 2C ) and lysosomes (LysoTracker; supplemental Figure 1 ). 
BPC NeuAc liposomes deliver cytotoxic cargo to Daudi human B lymphoma cells
The human Burkitt lymphoma Daudi B-cell line, commonly used for evaluating drugs for treatment of B-cell lymphomas, 33, 34 was next used to test the B-cell targeting of the BPC NeuAc liposomes. Binding assays were conducted at 37°C in 100% serum to mimic in vivo conditions. Liposomes without targeting ligands exhibit no detectable binding to Daudi cells, whereas liposomes with BPCNeuAc lipids show increased binding to the cells as the amount of ligand is increased from 0.8 to 5% (Figure 2D ). Binding and uptake of BPC NeuAc liposomes to Daudi cells is rapid, saturable, and competitively inhibited by the presence of free glycan ligands of CD22 ( Figure 2E-F) . When dox (adriamycin), a standard chemotherapeutic drug, was loaded into liposomes, the nontargeted naked liposomes exhibited a 175-fold reduction in cell killing relative to free dox, representing protection of the cells by encapsulation of the drug. In contrast, BPC NeuAc liposomes exhibited a 33-fold higher potency (IC 50 ϭ 1.6M) in cytotoxicity of Daudi cells ( Figure 2G ) than that of the naked liposomes (IC 50 ϭ 53M), a difference predictive of increased efficacy in vivo. 18 
Pharmacokinetics and siglec specificity of BPC NeuAc liposomes
In preparation for in vivo efficacy studies, the specificity of BPC NeuAc liposome binding to Daudi cells was assessed when spiked into an aliquot of mouse whole blood ( Figure 3A top panel) . Binding is specific for the Daudi cells (hCD19 ϩ ), with negligible binding to all murine cells (hCD19 Ϫ ), including murine B cells, because murine CD22 does not recognize the BPC NeuAc ligand. 25 In addition, BPC NeuAc liposomes injected intravenously 30 minutes after injection of 1 ϫ 10 6 Daudi cells also efficiently bound the hCD19 ϩ Daudi cells in the blood (Figure 3A bottom panel) . These results show BPC NeuAc liposomes efficiently target human B lymphoma cells both in vitro and in vivo.
In preliminary pharmacokinetics studies, we observed that the BPC NeuAc liposomes showed faster clearance from the blood relative to the naked liposomes in tumor-free animals ( Figure 3B ). We deduced that this was likely due to a known cross-reactivity of the BPC NeuAc ligand for another siglec, Sn (Siglec-1). 35, 36 Because Sn is expressed exclusively on tissue macrophages, 37 we repeated the pharmacokinetics in mice depleted of macrophages using liposomal clodronate. 32 This macrophage-specific treatment dramatically reduced clearance to that of naked liposomes ( Figure 3C ), demonstrating that clearance was indeed mediated by macrophages. To investigate this further, we tested binding against a panel of cell lines expressing human and murine siglecs, revealing that the BPC NeuAc liposomes did indeed bind to human (but not murine) CD22 (Siglec-2) and murine/human Sn ( Figure 3D ). To address the possibility that the sialylated ligand might be abrogating the "stealth" character of the liposomes, leading to nonspecific uptake by macrophages, we prepared liposomes containing a highly related ligand, BPA NeuAc, where the BPC substituent was replaced with a 9-N-biphenylacetyl (BPA), which binds poorly to Sn. 35, 36 As expected, the BPA NeuAc liposomes exhibited no binding to Sn while retaining binding to hCD22, albeit with reduced affinity ( Figure 3E ). These liposomes exhibited reduced clearance equivalent to that of the naked liposomes ( Figure 3F ), demonstrating that the ligand does not abrogate the stealth character of the liposomes. To confirm that the macrophage clearance of the BPC NeuAc liposomes was indeed mediated by Sn, we conducted pharmacokinetics in Sn-deficient mice, 38 which revealed minimal difference in the clearance rate of the BPC NeuAc and naked liposomes ( Figure  3G ). Thus, the rapid clearance of the BPC NeuAc liposomes is due to a specific and rapid uptake by macrophages mediated predominately by Sn. Although the BPA NeuAc liposomes exhibited higher specificity for CD22, their lower avidity reduces their binding to native Daudi cells ( Figure 3E ), precluding their use for investigation of efficacy in an in vivo model of human lymphoma. Accordingly, we envisioned the use of BPC NeuAc liposomes in a 2-dose protocol, assuming that uptake by macrophages would be blunted after the first dose, in analogy to the use of clodronate that ablated uptake of BPC NeuAc liposomes ( Figure 3C ).
BPC NeuAc liposomes prolong life in a murine model of human B-cell lymphoma
The efficacy of dox-loaded CD22 targeted liposomes was evaluated in a standard Daudi lymphoma model in SCID mice. 39 As illustrated by the timeline in Figure 4A , Daudi cells (5 ϫ 10 6 ) were injected intravenously and allowed to disseminate for 24 hours, followed by dosing mice on days 1 and 3 with PBS, dox-loaded naked liposomes, or BPC NeuAc liposomes (3 mg dox/kg per dose). As anticipated, pharmacokinetics analysis showed that rapid loss of BPC NeuAc liposomes from blood after the first dose was significantly attenuated after the second dose (supplemental Figure 2) . Untreated animals (PBS) had a mean time of survival (MTS) of 28.5 days, whereas the dox-loaded naked liposomes increased the MTS to 50 days. In contrast, liposomes displaying 2% BPC NeuAc ligands exhibited a MTS of 73 days, with 3 of 8 long-term survivors being healthy at the end of the study (day 100), and liposomes with 5% ligands demonstrated a MTS greater than 100 days with 5 of 8 long-term survivors. Both treatments with drug-loaded BPC NeuAc liposomes comprising 2% or 5% ligands proved significant in improving survival rates compared with the treatment of the nontargeted (naked) liposomal regimen. Follow-up analysis revealed that hCD19 ϩ Daudi cells constituted most bone marrow cells in paralyzed untreated or naked liposome-treated animals. In contrast, residual tumor cells were not detectable above background (Ig isotype control) in the bone marrow of the long-term survivors at day 100, further demonstrating the efficacy of the CD22-targeted liposomal regimen ( Figure 4B ; Table 1 ).
BPC NeuAc liposomes target B cells from blood of patients with lymphoma
We next analyzed the ability of the BPC NeuAc liposomes to bind to neoplastic B cells from patients with leukemia/lymphoma. As summarized in Table 2 , blood samples were obtained from 4 healthy donors and 30 patients with hairy cell leukemia (HCL), chronic lymphocytic leukemia (CLL), or splenic marginal zone lymphoma (MZL). These are 3 indolent lymphoproliferative disorders, known to express varying levels of CD22 (HCL, high; MZL, moderate; and CLL, low). 40, 41 Although most B cells in CLL and MZL samples are neoplastic cells, in the case of HCL, it is not uncommon to observe the normal and neoplastic B cells segregating into 2 distinct populations upon costaining with anti-CD22 and another B-cell marker (eg, CD19; Figure 5A ). When this was observed, neoplastic B cells were distinguished from the normal B cells by staining with anti-CD103 (expressed on most HCL cells and usually present on MZL cells), anti-CD5 (expressed on CLL cells), and anti-and anti-light chain probes 42 (data not shown).
All blood samples were assessed for their levels of B-cell expression of CD22 and the binding to the BPC NeuAc liposomes. In all cases, control naked liposomes bound no better to the CD19 ϩ B cells than the non-B cells ( Figure 5A ; supplemental Figure 3 ). In 5C). The assay involves exposure of the peripheral blood leukocytes to the liposomal preparations for 1 hour, followed by incubation of the cells for 5 days in media. Cell viability was assessed using a standard MTT assay. Whereas HCL and MZL were susceptible to both low (10M) and high (40M) concentrations of the targeted liposomal dox, CLL cells were efficiently killed only by the higher dox concentration. Taken together, the results indicate that while binding of the CD22-targeted liposome to malignant B cells is proportional to CD22 expression on the cell surface, even low levels of expression on CLL cells are sufficient to effect cell killing. Because the targeted liposomes breach the cells by an endocytic mechanism, it is anticipated that the therapeutic benefit will be synergistic with anti-CD20 rituximab and other immune-mediated therapies.
Discussion
Two families of glycan-binding proteins, the siglecs and C-type lectins, are recognized as attractive targets for cell-directed therapies because they exhibit restricted expression to 1 or a few cell types, and are predominately expressed on leukocytes or endothelial cells that can be exploited for modulation of the immune system and treatment of inflammatory disease. 24, 43 A disadvantage is that glycan-binding proteins typically have low affinity for their glycan ligands, which pose constraints for the design of ligandbased targeting agents. 44, 45 In this report, we demonstrate that dox-loaded liposomal nanoparticles displaying high-affinity glycan ligands of human CD22 (Siglec-2) efficiently target human B cells in an in vivo murine model of human lymphoma.
We have found that multivalent presentation of high-affinity CD22 ligands on liposomes is the only multivalent platform to date that generates sufficient avidity to target B cells in a complex biologic milieu. It is well documented that endogenous cis ligands on B cells mask binding of synthetic ligands to CD22 in trans unless cells are first treated with sialidase. 44, 46 However, we have previously demonstrated that multivalent display of the highaffinity ligand ( BPC NeuAc) on a polyacrylamide polymer could complete with cis ligands, and to bind to CD22 on native B cells. 25 Similarly, a heterobifunctional ligand comprising an antigen, nitrophenol (NP), coupled to the BPC NeuAc ligand could use an anti-NP antibody as a scaffold to assemble immune complexes with CD22 on B cells. 26 However, subsequent analysis showed that neither of these multivalent complexes could bind to B cells in 100% serum, abrogating their use for targeting B cells in vivo (data not shown). In contrast, the ligand-decorated liposomes not only bound to native cells, but also bound well to B cells in serum in vitro and in vivo. Thus, the liposomes provide a robust scaffold that is unique for targeting CD22 on B cells in a physiologically relevant setting.
Liposomal formulations of doxorubicin are currently approved for treatment of solid tumors, acting to prolong circulatory half-life, and concentrate in tumor tissue by escaping the blood through leaky blood vessels. In contrast, BPC NeuAc liposomes loaded with dox effectively target B cells by binding to and being endocytosed by CD22, carrying their toxic cargo into the cell (Figure 2 ). The effect of active targeting is clearly seen when comparing in vivo efficacy of the "naked" and ligand-decorated liposomes in a disseminated model of human B-cell lymphoma on SCID mice ( Figure 4A ). The ligand-targeted liposomes significantly prolonged the lives of tumor-bearing animals compared with the nontargeted liposomal dox. The results support the strategy for developing a new use for an approved drug by converting the delivery mechanism to active targeting and uptake by a targeted cell. This concept is of direct therapeutic interest for treatment of non-Hodgkin lymphoma or other B-cell lymphomas, with more than a dozen clinical trials completed or in progress evaluating liposomal dox in place of dox for standard cyclophosphamide, doxorubicin, prednisone, and vincristine (CHOP) chemotherapy. [47] [48] [49] Although the BPC NeuAc liposomes proved strong efficacy in the B-cell lymphoma model, there is room for further improving the selectivity and effectiveness of the targeting ligand. These liposomes have a known cross-reactivity with Sn (Siglec-1) expressed on tissue macrophages, which effectively compete for liposomes in the in vivo experiments, limiting the amount available for targeting to the human B lymphoma. No other siglec appears to play a significant role in the clearance of liposomes in wild-type mice, because rapid clearance is not seen in macrophage-depleted mice and in Sn knockout mice (Figure 3) . Thus, liposomes bearing ligands that do not bind to Sn and retain affinity for CD22 would be expected to exhibit significantly improved targeting of human B cells.
Several reports combined with the results presented here suggest that glycan ligand-decorated liposomes may provide a robust platform with unique properties for targeted delivery of therapeutic agents to cells that express the cognate glycanbinding protein. [20] [21] [22] [23] [24] 43 We suggest that design of glycan ligands that will target a single glycan-binding protein is within reach, and that additional examples of successful targeting using the pharmaceutically proven liposomal nanoparticle platform will stimulate their consideration as an option to antibodies for targeted therapeutics.
